Core Insights - BioAtla, Inc. reported its financial results for the full year and fourth quarter ended December 31, 2025, highlighting a focus on advancing its clinical programs while exploring strategic options to maximize shareholder value [1][3]. Corporate Updates - The company initiated a formal process to explore strategic options, including the potential sale of assets and partnerships, engaging Tungsten Advisors as its exclusive financial advisor [3]. - A reduction in force and cost-containment measures were implemented to align resources with near-term priorities, affecting the timing and scope of clinical development programs [4]. - The ongoing Phase 1 study of BA3182 in adenocarcinomas remains a priority, with the company committed to its clinical development despite potential delays [4]. Financial Results - Research and development (R&D) expenses for Q4 2025 were $8.0 million, down from $11.7 million in Q4 2024. For the full year, R&D expenses totaled $43.6 million, compared to $63.1 million in 2024, primarily due to lower program development costs and reduced headcount-related expenses [5]. - Collaboration and other revenue for Q4 2025 was $2.0 million, reflecting a milestone payment from Context Therapeutics, compared to $11.0 million for the full year 2024 [6]. - General and administrative (G&A) expenses decreased to $3.3 million in Q4 2025 from $4.6 million in Q4 2024, with full-year G&A expenses at $17.7 million compared to $21.8 million in 2024 [7]. - The net loss for Q4 2025 was $9.8 million, an improvement from a net loss of $14.9 million in Q4 2024. The full-year net loss was $59.6 million, down from $69.8 million in 2024 [8]. Cash Position - As of December 31, 2025, cash and cash equivalents were $7.1 million, a significant decrease from $49.0 million at the end of 2024 [10][23]. - The company expects to extend its runway through cost reductions and the utilization of a Standby Equity Purchase Agreement while pursuing strategic options [10]. Clinical Pipeline - BioAtla is advancing several clinical assets, including BA3182, a bispecific T-cell engager antibody for advanced adenocarcinoma, and Ozuriftamab Vedotin (Oz-V), targeting oropharyngeal squamous cell carcinoma [13][15]. - Oz-V has received Fast Track Designation from the FDA for treating recurrent or metastatic squamous cell carcinoma of the head and neck, with a potential market opportunity exceeding $7 billion [15]. Patent Portfolio - BioAtla holds extensive patent coverage for its CAB platform technology, with over 780 active patent matters, including more than 500 issued patents, covering various methods and compositions related to its product candidates [11].

Core Viewpoint - BioAtla, Inc. is exploring strategic options to maximize shareholder value, including potential asset sales and partnerships, while implementing a significant restructuring plan to reduce operating expenses by approximately 70% [1][2]. Company Overview - BioAtla is a clinical-stage biotechnology company based in San Diego, focusing on Conditionally Active Biologic (CAB) antibody therapeutics for solid tumors [3]. - The company utilizes a proprietary CAB platform technology to develop novel monoclonal and bispecific antibodies, aiming for selective targeting and reduced toxicity compared to traditional antibodies [3]. - BioAtla holds over 780 active patent matters, with more than 500 issued patents, covering methods of making and manufacturing CAB product candidates [3]. Clinical Pipeline - BioAtla's clinical pipeline includes several assets at various stages: - Ozuriftamab vedotin (CAB-ROR2-ADC) is in Phase 3 for treating oropharyngeal squamous cell carcinoma (OPSCC) and has potential applications in HPV+ cancers, representing a market opportunity of over $7 billion [8]. - Mecbotamab vedotin (CAB-AXL-ADC) is in Phase 2 for multiple solid tumor indications, including mKRAS NSCLC and soft tissue sarcoma [10]. - Evalstotug (CAB-CTLA-4) is in Phase 2, designed for safer combination therapies with anti-PD-1 agents [11]. - BA3182 (CAB-EpCAM x CAB-CD3) is in Phase 1 for advanced adenocarcinoma [7]. Strategic Actions - The company has engaged Tungsten Advisors as its exclusive strategic financial advisor to assist in evaluating potential transactions [2]. - The restructuring plan aims to retain essential employees while significantly reducing the workforce to enhance cost containment [1].

Core Insights - BioAtla and GATC Health have initiated a $40 million special purpose vehicle (SPV) transaction to advance Ozuriftamab vedotin (Oz-V) into a Phase III trial for second-line and later oropharyngeal squamous cell carcinoma (OPSCC) [1] - BioAtla will receive an initial payment of $5 million from Inversagen AI, which is focused on age-related disease research, to cover general operating and trial expenses [1] - The remaining $35 million is expected to close in the first quarter of 2026, coinciding with the launch of the Oz-V registrational clinical study [3] Company and Partnership Details - Inversagen AI was formed by GATC Health and Inversagen, holding exclusive license rights to senescence AI longevity technologies and BioAtla's conditionally active biologic (CAB) technologies [2] - Upon completion of the transaction, Inversagen AI will own a 35% stake in Oz-V, while BioAtla retains 65% ownership across all Oz-V solid tumor indications [3] - BioAtla and GATC Health will collaborate with Inversagen AI on research and development of CAB senolytic therapies, while BioAtla maintains rights to cancer therapeutic applications [4] Future Developments - BioAtla anticipates beginning enrollment for the Phase III pivotal trial in early 2026, with a clear registrational path and potential for accelerated approval in the US [4] - Discussions are ongoing with potential partners to expand the application of Oz-V into HPV-positive solid tumors, including cervical cancer [4] - In July 2025, BioAtla presented Phase I study data for its anti-cancer therapy, BA3182, targeting treatment-refractory metastatic adenocarcinoma [4]

Core Viewpoint - BioAtla, Inc. has secured a total of $7.5 million in advance funding through agreements with Yorkville Advisors and Anson Advisors, aimed at maintaining operational momentum while finalizing a strategic partnership that is expected to enhance shareholder value [1][2][7] Financial Agreements - The pre-paid advance agreement involves $7.5 million purchased at 95% of face value, resulting in gross proceeds of $7.125 million at closing, with an interest rate of 4% [2] - The Standby Equity Purchase Agreement allows Yorkville to purchase up to $15 million of common stock at a 3% discount to market prices over three years, contingent on certain conditions [1][2] Strategic Partnership - The company is in advanced stages of finalizing a strategic transaction with a potential partner, with expectations to complete this by year-end [2][7] - These financial agreements are designed to provide flexibility and support operations during the partnership finalization process [7] Company Overview - BioAtla is a clinical-stage biotechnology company focused on developing Conditionally Active Biologic (CAB) antibody therapeutics for solid tumors, with operations in San Diego and Beijing [6] - The company utilizes its proprietary CAB platform technology to create novel monoclonal and bispecific antibodies, aiming for selective targeting and reduced toxicity compared to traditional antibodies [6] Product Pipeline - Ozuriftamab vedotin (Oz-V) is a key clinical asset targeting ROR2 in various solid tumors, with FDA Fast Track Designation for recurrent or metastatic SCCHN [8] - BA3182, a bispecific T-cell engager antibody, is under Phase 1 study for advanced adenocarcinoma, designed for selective binding in the tumor microenvironment [9]

Financial Data and Key Metrics Changes - As of September 30, 2025, the company reported cash and cash equivalents of $8.3 million, which does not include a recent $2 million milestone payment received in October 2025 [12] - The net loss for the third quarter of 2025 was $15.8 million, an increase from a net loss of $10.6 million in the same quarter of 2024, primarily due to the absence of collaboration revenue recorded in 2024 [12][13] - Research and development (R&D) expenses decreased to $9.5 million in Q3 2025 from $16.4 million in Q3 2024, driven by reduced program development costs and lower headcount-related expenses [13] - General and administrative (G&A) expenses were $4.2 million for Q3 2025, down from $5.9 million in Q3 2024, attributed to reduced personnel costs [14] Business Line Data and Key Metrics Changes - The company is preparing to initiate a phase 3 study for OSV, which has shown promising clinical activity in heavily pretreated patients with HPV-positive oropharyngeal squamous cell carcinoma (OPSCC) [5][7] - The dual CAB, EpCAM, T-cell engager program is progressing well, with preliminary data indicating a manageable safety profile and encouraging signs of tumor reductions across various indications [10] Market Data and Key Metrics Changes - The worldwide peak sales estimate for OSV in second-line and later OPSCC is approximately $800 million, with the total worldwide OPSCC market projected to reach $3 billion by 2032 [7] - The broader HPV-positive solid tumor market, including cervical cancer, is valued at over $7 billion globally [8] Company Strategy and Development Direction - The company is in advanced stages to finalize a strategic transaction with a potential partner by year-end, indicating a focus on collaboration and partnerships [4][5] - The company aims to address critical unmet needs in oncology through its prioritized programs, particularly the dual CAB, EpCAM, TCE program, which has the potential to treat over 1 million adenocarcinoma cancer patients annually [15] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the upcoming phase 3 trial for OPSCC, which addresses a significant unmet need and represents a substantial commercial opportunity [15] - The company anticipates key clinical trial readouts in the first half of next year, with several important events related to its programs throughout 2026 [15] Other Important Information - The company achieved FDA alignment on the phase 3 OSV registrational trial design, which includes dual primary endpoints of overall response rate and overall survival [4][5] - A development milestone was achieved under the license agreement with Context Therapeutics, validating the T-cell engager platform [5] Q&A Session Summary Question: Can you provide details on the patient number for the ROR-2 program's phase 3 study and control arm stratification? - The pivotal trial design for full approval involves approximately 300 patients, with an interim analysis for accelerated approval occurring earlier [18][19] Question: What data can be expected from the 3182 program next year? - The next data output is anticipated in the first half of next year, with comprehensive reporting on additional dose and schedule evaluations [21][22]

Core Insights - BioAtla, Inc. reported its financial results for Q3 2025, highlighting progress in clinical programs and a strategic partnership expected to be finalized by year-end [1][2][4]. Financial Performance - Research and development (R&D) expenses decreased to $9.5 million in Q3 2025 from $16.4 million in Q3 2024, primarily due to lower program development costs and workforce reductions [8]. - General and administrative (G&A) expenses also fell to $4.2 million in Q3 2025 from $5.9 million in Q3 2024, attributed to reduced personnel costs [10]. - The net loss for Q3 2025 was $15.8 million, compared to a net loss of $10.6 million in Q3 2024, with the increase largely due to the absence of collaboration revenue recorded in the previous year [11]. Clinical Developments - The company achieved FDA alignment on the Phase 3 trial design for Ozuriftamab vedotin (Oz-V) targeting 2L+ oropharyngeal squamous cell carcinoma (OPSCC), with potential for accelerated approval [4][5]. - Ongoing trials for BA3182 in advanced adenocarcinomas are evaluating various dosing schedules, with preliminary data showing prolonged tumor control [5][8]. - The Phase 2 study of Mecbotamab vedotin (Mec-V) reported a median overall survival of 21.5 months among patients with treatment-refractory soft tissue sarcomas [5][14]. Strategic Initiatives - BioAtla is in advanced stages of finalizing a strategic transaction with a potential partner, aiming for completion by the end of 2025 [4][11]. - A $2 million milestone payment was triggered by Context Therapeutics under the license agreement for the CAB-Nectin4-TCE program, reflecting progress in the T-cell engager platform [9]. Upcoming Milestones - The company expects to initiate the Oz-V Phase 3 study in early 2026 and anticipates additional readouts from ongoing trials later in 2026 [5][8].

Core Insights - BioAtla, Inc. announced preliminary clinical data from a Phase 1 study of BA3182, a bispecific T-cell engager targeting EpCAM and CD3, at the ESMO Congress 2025, highlighting its potential for treating treatment-refractory metastatic adenocarcinoma [1][3] Group 1: Clinical Data and Efficacy - BA3182 shows a manageable safety profile with preliminary evidence of antitumor activity [4] - Prolonged tumor control observed with increasing doses of BA3182, including a confirmed partial response at 0.6 mg in a patient with intrahepatic cholangiocarcinoma without progression for over 6 months [6] - Among patients treated at doses of 0.6 mg and higher, there was a higher rate of stable disease and prolonged treatment intervals compared to those receiving lower doses [13] Group 2: Safety Profile - Adverse events were generally transient and manageable, with only 2 cases of cytokine release syndrome reported [6] - No treatment-related deaths occurred, and only one patient discontinued treatment due to an adverse event [6] - Safety profile supports continued dose escalation, with the maximally tolerated dose not yet defined [6] Group 3: Technology and Mechanism - BA3182 is designed to selectively bind within the acidic tumor microenvironment, reducing on-target, off-tumor toxicity associated with traditional antibodies [2][9] - The CAB technology utilized by BioAtla activates only in diseased microenvironments, aiming for more selective targeting and lower toxicity compared to conventional therapies [10] Group 4: Market Potential - BA3182 has the potential to serve over one million patients globally, indicating a significant market opportunity for BioAtla [3]

Core Viewpoint - BioAtla, Inc. is set to discuss its financial results for Q2 2025 and provide business highlights during a conference call on August 7, 2025 [1][2] Company Overview - BioAtla is a global clinical-stage biotechnology company focused on developing Conditionally Active Biologic (CAB) antibody therapeutics for solid tumors [1][3] - The company operates in San Diego, California, and Beijing, China, through a partnership with BioDuro-Sundia for preclinical development services [3] - BioAtla utilizes its proprietary CAB platform technology to create novel monoclonal and bispecific antibodies, aiming for selective targeting, greater efficacy, lower toxicity, and cost-efficient manufacturing compared to traditional antibodies [3] - The company holds extensive patent coverage with over 780 active patent matters, including more than 500 issued patents, covering methods of making, screening, and manufacturing CAB product candidates [3] Product Development - BioAtla's first dual CAB bispecific T-cell engager antibody, BA3182, is in Phase 1 development, targeting EpCAM, which is commonly expressed in adenocarcinomas [3] - The company has two first-in-class CAB programs in Phase 2 clinical testing: mecbotamab vedotin (CAB-AXL-ADC) and ozuriftamab vedotin (CAB-ROR2-ADC) [3] - The Phase 2 CAB-CTLA-4 antibody, evalstotug, is designed to reduce systemic toxicity and enable safer combination therapies with checkpoint inhibitors like anti-PD-1 antibody [3]

Core Insights - BioAtla, Inc. is a clinical-stage biotechnology company focused on developing Conditionally Active Biologic (CAB) antibody therapeutics for solid tumors [1][3] - The company will present a first-in-human phase I study of a dual-CAB EpCAM x CD3 bispecific T-cell engager (TCE), BA3182, targeting treatment refractory metastatic adenocarcinoma at the 2025 ESMO TAT Asia Meeting [2] Company Overview - BioAtla operates in San Diego, California, and has a presence in Beijing, China through a partnership with BioDuro-Sundia for preclinical development services [3] - The company utilizes its proprietary CAB platform technology to develop novel monoclonal and bispecific antibodies, aiming for selective targeting, greater efficacy, lower toxicity, and cost-efficient manufacturing compared to traditional antibodies [3] - BioAtla holds extensive patent coverage with over 780 active patent matters, including more than 500 issued patents, covering methods of making, screening, and manufacturing CAB product candidates [3]

Core Insights - BioAtla, Inc. reported its financial results for Q1 2025, highlighting advancements in its Conditionally Active Biologic (CAB) platform and ongoing clinical trials for cancer therapies [1][8]. Financial Performance - Research and development (R&D) expenses for Q1 2025 were $12.4 million, down from $18.9 million in Q1 2024, primarily due to reduced clinical development costs [8]. - General and administrative (G&A) expenses decreased to $5.3 million in Q1 2025 from $5.6 million in Q1 2024 [9]. - The net loss for Q1 2025 was $15.3 million, compared to a net loss of $23.2 million in the same quarter of 2024 [9]. - Cash and cash equivalents as of March 31, 2025, were $32.4 million, down from $49.0 million at the end of 2024, with expectations to fund operations through key clinical readouts in 1H 2026 [11]. Clinical Developments - The Phase 1 dose-escalation study for CAB-EpCAM x CAB-CD3 (BA3182) is ongoing, with the first three patients dosed at 300 micrograms, and data readout expected in mid-2025 [5][6]. - Mecbotamab vedotin (Mec-V) demonstrated a 2-year landmark survival rate of 59% in mKRAS non-small cell lung cancer (NSCLC) patients, significantly higher than the less than 20% survival rate reported for standard care [5][6]. - Ozuriftamab vedotin (Oz-V) continues to show promising results in HPV-positive squamous cell carcinoma of the head and neck, with a disease control rate of 100% and an overall response rate of 45% [6][5]. Strategic Initiatives - The company is utilizing Fast Track Designation from the FDA for discussions regarding a proposed Phase 3 study for Oz-V in treatment-refractory metastatic HPV-positive SCCHN [13]. - BioAtla is focusing on its two internal priority programs and expects cost reductions from its recent restructuring [11]. Upcoming Events - Management will host a conference call and webcast on May 6, 2025, to discuss the financial results and clinical updates [12]. - BioAtla has presentations scheduled at major oncology conferences, including the ASCO Annual Meeting and ESMO Gastrointestinal Cancers Congress [13].